FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
17/11/2024
Voltar para busca
Dado oficial do USPTO
CENYX BIOTECH
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CENYX BIOTECH
ST13
US500000079343374Classe
5, 42
Pedido
79343374
Registro
7333739
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
17/11/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
29/04/2022
Data de registro
26/03/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/03/2024
Última transação
26/03/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
KR
Examinador
SIMCOX,KYLE DUNCAN
Unidade examinadora
N40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Cenyx Biotech Inc.
Representantes
Leigh Ann Lindquist SUGHRUE MION, PLLC
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Diagnostic reagents for medical or veterinary purposes; diagnostic preparations for medical or veterinary purposes; veterinary preparations for the treatment of infectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organs and certain disorders involving the immune mechanismendocrinenutritional and metabolic diseasesmental and behavioural disordersdiseases of the nervous systemdiseases of the eye and adnexadiseases of the ear and mastoid processdiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary systemcongenital malformationsdeformations and chromosomal abnormalitiesinjurypoisoning and certain other consequences of external causes for animal and poultry; radio-isotope markers for therapeutic or diagnostic use; in vitro diagnostic preparations for medical purposes; vaccines; contrast media for use in medical imaging equipment; contrast media for in vivo imaging; drug delivery agents in the form of compoundswrapping wafersedible wafers that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations for the prevention of inflammatory disorders; non-prescription medicinesmedicinal preparations in the nature of pillstabletscapsulescapletsliquid dropssachetsoral liquidssuspensionsliquidssemi-solidscreamssyrupsointmentslotionsgelsspraysemulationsoilspessariessuppositoriesgranules and films for the treatment of infectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organs and certain disorders involving the immune mechanismendocrinenutritional and metabolic diseasesmental and behavioural disordersdiseases of the nervous systemdiseases of the eye and adnexadiseases of the ear and mastoid processdiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary systemcongenital malformationsdeformations and chromosomal abnormalitiesinjurypoisoning and certain other consequences of external causes; radioactive pharmaceutical preparations for use in vivo diagnostics or therapeutic use; diagnostic agents for medical purposes; biological preparations for medical purposesbiological preparations for the treatment of infectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organs and certain disorders involving the immune mechanismendocrinenutritional and metabolic diseasesmental and behavioural disordersdiseases of the nervous systemdiseases of the eye and adnexadiseases of the ear and mastoid processdiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary systemcongenital malformationsdeformations and chromosomal abnormalitiesinjurypoisoning and certain other consequences of external causes for medical or veterinary purposes; pharmaceuticals for the treatment of infectious and parasitic diseasesneoplasmsdiseases of the blood and blood-forming organs and certain disorders involving the immune mechanismendocrinenutritional and metabolic diseasesmental and behavioural disordersdiseases of the nervous systemdiseases of the eye and adnexadiseases of the ear and mastoid processdiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary systemcongenital malformationsdeformations and chromosomal abnormalitiesinjurypoisoning and certain other consequences of external causes; pharmaceutical preparations for the prevention of disorders of the cardio-vascular system; pharmaceutical preparations for the treatment of cardiovascular disease; drug delivery agents in the form of tablets or capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceutical preparations for the treatment of inflammatory diseases; antibodies for medical purposes
Classe 42
Scientific research in the nature of conducting clinical trials for others in the field of cardiovascular disease; scientific research for medical purposes in the field of cancerous diseases; pharmaceutical research and development; Scientific research in the nature of conducting clinical trials for others in the field of medicine; analysisevaluation of medical product development services of others to assure compliance with industry standards; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of pharmacy
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/10/2024
FIMP
FINAL DISPOSITION PROCESSED
06/10/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
27/06/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
26/03/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
26/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/01/2024
PUBO
PUBLISHED FOR OPPOSITION
09/01/2024
GPNX
NOTIFICATION PROCESSED BY IB
08/01/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
20/12/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
20/12/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/12/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
18/12/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
29/11/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
29/11/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
29/11/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
29/11/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
29/11/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
29/11/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
29/11/2023
DOCK
ASSIGNED TO EXAMINER
07/11/2023
DOCK
ASSIGNED TO EXAMINER
05/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/10/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/10/2023
RFNT
REFUSAL PROCESSED BY IB
24/05/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
30/04/2023
RFRR
REFUSAL PROCESSED BY MPU
30/04/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/03/2023
CNRT
NON-FINAL ACTION WRITTEN
10/03/2023
DOCK
ASSIGNED TO EXAMINER
17/02/2023
MAFR
APPLICATION FILING RECEIPT MAILED
28/06/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/06/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
23/06/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CENYX BIOTECH ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.